 I announce that the Senator from Illinois (Ms. Duckworth)  and the Senator from New Mexico (Mr. Heinrich) are necessarily absent.    Mr. President, I ask unanimous consent that the text of  the bill be printed in the Record.   There being no objection, the text of the bill was ordered to be  printed in the Record, as follows:                                  S. 2535         Be it enacted by the Senate and House of Representatives of       the United States of America in Congress assembled,       SECTION 1. SHORT TITLE.         This Act may be cited as the ``Opioid Quota Reform Act''.       SEC. 2. STRENGTHENING CONSIDERATIONS FOR DEA OPIOID QUOTAS.         Section 306 of the Controlled Substances Act (21 U.S.C.       826) is amended--        (1) in the last sentence of subsection (a), by striking ``       and not in terms of individual pharmaceutical dosage forms       prepared from or containing such a controlled substance'';       and        (2) by adding at the end the following:        ``(i)(1) In fixing and adjusting production and       manufacturing quotas under this section for fentanyl,       oxycodone, hydrocodone, oxymorphone, and hydromorphone, the       Attorney General shall consider the impact of the production       and manufacturing quotas on overall public health and rates       of diversion, abuse, and overdose deaths related to these       controlled substances in the United States. Any of the       considerations in this subsection or in subsection (a) may be       used to determine changes to levels of such production and       manufacturing quotas in a given year.        ``(2)(A) For any year in which the approved production       quota for fentanyl, oxycodone, hydrocodone, oxymorphone, or       hydromorphone is higher than the approved production quota       for the substance in the previous year, the Attorney General       shall include in its final order an explanation of why the       public health benefits of increasing such quota outweigh the       consequences of having an increased volume of such substance       available for sale, and potential diversion, in the United       States.        ``(B) Not later than 1 year after the date of enactment of       this subsection and every year thereafter, the Attorney       General shall provide to the Caucus on International       Narcotics Control, Committee on the Judiciary, Committee on       Health, Education, Labor, and Pensions, and Committee on       Appropriations of the Senate and the Committee on the       Judiciary, Committee on Energy and Commerce, and Committee on       Appropriations of the House of Representatives, the following       information with regard to each of the substances described       in subparagraph (A):        ``(i) An anonymized count of the total number of       manufacturers issued individual manufacturing quotas that       year for that substance.        ``(ii) A count of how many such manufacturers were issued       an approved manufacturing quota that was higher than the       quota issued to that manufacturer for that substance in the       previous year.        ``(3) Not later than 180 days after the date of enactment       of this subsection, the Attorney General shall submit to       Congress a report on how the Attorney General will ensure       that the annual process of fixing and adjusting production       and manufacturing quotas under this section takes into       consideration--        ``(A) efforts to reduce the costs, injuries, and deaths       associated with the diversion and abuse of prescription       opioids and heroin, including changes in the accepted medical       use of certain controlled substances; and        ``(B) data collection and evaluation of the volume of       controlled substances that are diverted and collected from       approved drug collection receptacles, mail-back programs, and       take-back events.''.                                  ______                                         By Mr. FLAKE:   S. 2538. A bill to prohibit an increase in duties on imports of steel  and aluminum; to the Committee on Finance.    Mr. President, I ask unanimous consent that the text of  the bill be printed in the Record.   There being no objection, the text of the bill was ordered to be  printed in the Record, as follows:                                  S. 2535         Be it enacted by the Senate and House of Representatives of       the United States of America in Congress assembled,       SECTION 1. SHORT TITLE.         This Act may be cited as the ``Opioid Quota Reform Act''.       SEC. 2. STRENGTHENING CONSIDERATIONS FOR DEA OPIOID QUOTAS.         Section 306 of the Controlled Substances Act (21 U.S.C.       826) is amended--        (1) in the last sentence of subsection (a), by striking ``       and not in terms of individual pharmaceutical dosage forms       prepared from or containing such a controlled substance'';       and        (2) by adding at the end the following:        ``(i)(1) In fixing and adjusting production and       manufacturing quotas under this section for fentanyl,       oxycodone, hydrocodone, oxymorphone, and hydromorphone, the       Attorney General shall consider the impact of the production       and manufacturing quotas on overall public health and rates       of diversion, abuse, and overdose deaths related to these       controlled substances in the United States. Any of the       considerations in this subsection or in subsection (a) may be       used to determine changes to levels of such production and       manufacturing quotas in a given year.        ``(2)(A) For any year in which the approved production       quota for fentanyl, oxycodone, hydrocodone, oxymorphone, or       hydromorphone is higher than the approved production quota       for the substance in the previous year, the Attorney General       shall include in its final order an explanation of why the       public health benefits of increasing such quota outweigh the       consequences of having an increased volume of such substance       available for sale, and potential diversion, in the United       States.        ``(B) Not later than 1 year after the date of enactment of       this subsection and every year thereafter, the Attorney       General shall provide to the Caucus on International       Narcotics Control, Committee on the Judiciary, Committee on       Health, Education, Labor, and Pensions, and Committee on       Appropriations of the Senate and the Committee on the       Judiciary, Committee on Energy and Commerce, and Committee on       Appropriations of the House of Representatives, the following       information with regard to each of the substances described       in subparagraph (A):        ``(i) An anonymized count of the total number of       manufacturers issued individual manufacturing quotas that       year for that substance.        ``(ii) A count of how many such manufacturers were issued       an approved manufacturing quota that was higher than the       quota issued to that manufacturer for that substance in the       previous year.        ``(3) Not later than 180 days after the date of enactment       of this subsection, the Attorney General shall submit to       Congress a report on how the Attorney General will ensure       that the annual process of fixing and adjusting production       and manufacturing quotas under this section takes into       consideration--        ``(A) efforts to reduce the costs, injuries, and deaths       associated with the diversion and abuse of prescription       opioids and heroin, including changes in the accepted medical       use of certain controlled substances; and        ``(B) data collection and evaluation of the volume of       controlled substances that are diverted and collected from       approved drug collection receptacles, mail-back programs, and       take-back events.''.                                  ______   